Taking together, these observations strongly suggest that the p53 target gene set contained within the predictive 13-gene signature is representative of an underlying activated p53 pathway that renders cancer cell lines and patient-derived tumor xenografts sensitive to p53–HDM2 inhibitors. Here, TP53 is linked to neoplasm.